UK Researchers Unveil Groundbreaking Cancer Mutation Map
The Institute of Cancer Research (ICR) in London and the University of Manchester have led a monumental effort to map the genetic mutations driving cancer, producing the most detailed catalogue to date. Published in Nature Genetics in February 2026, this study analyzed whole-genome sequencing data from 10,983 tumors across 16 cancer types, sourced from nearly 11,000 National Health Service (NHS) patients through Genomics England's 100,000 Genomes Project. By cataloguing 370 million mutations spanning the entire three billion base pairs of the human genome, researchers identified 134 distinct mutational signatures—characteristic patterns of DNA alterations left by underlying biological processes that damage genetic material.
This comprehensive approach goes beyond previous efforts, which primarily focused on single-base changes. The team incorporated five mutation classes: single-base substitutions (SBS), doublet-base substitutions (DBS), insertions and deletions (ID), copy number alterations (CN), and structural variants (SV). Among these, 26 signatures were entirely new to the Catalogue of Somatic Mutations in Cancer (COSMIC), including 10 novel SV signatures.
The scale and depth of this analysis provide unprecedented insights into tumor evolution, etiology, and therapeutic vulnerabilities, positioning UK higher education institutions at the forefront of cancer genomics.
Understanding Mutational Signatures: The Genetic Fingerprints of Cancer
Mutational signatures are like forensic fingerprints in a cancer's DNA, revealing the 'stories' of how tumors develop. Each signature arises from specific mutagenic processes, such as ultraviolet light exposure (causing C>T transitions), tobacco smoke (G>T transversions), or defective DNA repair mechanisms. Step-by-step, these processes work as follows:
- Carcinogens or endogenous errors damage DNA during replication or repair.
- Cells fail to correct the damage accurately, imprinting repeatable patterns across the genome.
- Over time, these accumulate, driving oncogenic mutations in key genes like TP53 or BRCA1/2.
- Whole-genome sequencing captures the full spectrum, unlike targeted panels that miss complex rearrangements.
Prior catalogues, like COSMIC's version 3, listed around 100 signatures. This study expands to 134 by analyzing diverse mutation types and transcriptional strand bias, enhancing resolution for clinical use.
The Massive Dataset: 100,000 Genomes Project Powers Discovery
Leveraging the NHS's 100,000 Genomes Project—a flagship initiative pairing genomic data with clinical records—the researchers examined tumors from diverse UK patients. The 16 cancer types included breast, ovarian, colorectal, lung, prostate, skin, kidney, bladder, uterine, sarcoma, central nervous system, hepatopancreatobiliary, esophageal, head and neck, thyroid, and hematological malignancies.
Advanced computational methods, including non-negative matrix factorization for signature extraction and hierarchical clustering for associations, revealed how signatures correlate with genomic features like whole-genome doubling and chromothripsis. Code and methods are openly available on GitHub, fostering reproducibility in UK academic labs.
134 Signatures: Cataloguing Cancer's Mutagenic Arsenal
The study's centerpiece is the identification of 134 signatures, expanding SBS to 288 classes by transcriptional context. Notable new ones include SBS96–98 (linked to unknown processes), DBS13–19, ID19–22, CN25, and SV7–10. Clustering showed clear groupings:
| Cluster | Key Signatures | Associated Process |
|---|---|---|
| UV Exposure | SBS7, SBS17 | Skin cancers |
| Tobacco | SBS4, DBS2 | Lung, bladder |
| Homologous Recombination Deficiency (HRD) | ID2–6, SV deletions | Breast, ovarian |
| Deficient Mismatch Repair (dMMR) | SBS15, MSH6 inactivation | Colorectal |
| APOBEC | SBS2, SBS13 | Multiple types |
These patterns not only trace causes but predict timing—exogenous mutagens like UV act early (clonal), while endogenous like dMMR emerge later (subclonal).
HRD Signatures Unlock PARP Inhibitors for Thousands More Patients
One of the most clinically actionable findings is the prevalence of HRD signatures beyond BRCA1/2 mutations. HRD—Homologous Recombination Deficiency—impairs double-strand break repair, sensitizing tumors to PARP inhibitors (e.g., olaparib) and platinum chemotherapy.
- 17% of breast cancers showed HRD signatures, potentially qualifying over 7,700 UK patients annually.
- 30% of ovarian cancers, over 1,000 patients.
- Linked to higher tumor grade and BRCAness phenotypes.
Currently, only BRCA-tested patients access these; signatures expand eligibility, as validated by associations with gene inactivations and treatment responses. Professor David Wedge noted: “By analysing the entire genome... we can make better predictions about which treatments are most likely to benefit individual patients.” See the full study for details: Nature Genetics paper.
Photo by Dylan Patterson on Unsplash
Microbial Toxins and the Rise of Early-Onset Colorectal Cancer
A striking observation: a signature tied to bacterial colibactin toxins (from certain E. coli strains) appears more in younger colorectal cancer patients. This supports hypotheses that gut microbiome dysbiosis contributes to the 2-4% annual rise in under-50s bowel cancer incidence in the UK.
Professor Richard Houlston (ICR) explained: “Several mutational signatures occur significantly more frequently in younger patients... pointing to a potential role for the microbiome.” This could spur microbiome-targeted prevention or therapies.
Beyond HRD: dMMR, APOBEC, and Survival Insights
Other signatures illuminate therapeutic opportunities:
- dMMR signatures in 18% colorectal cancers predict immunotherapy response (e.g., pembrolizumab).
- APOBEC in 29% tumors links to ATR inhibitor sensitivity; associated with radiotherapy response.
- POLE mutations drive ultramutated tumors responsive to checkpoint inhibitors.
Survival analyses showed HRD/APOBEC worsening outcomes in breast cancer, while SBS17b (unknown etiology) reduced survival in colorectal.
More at ICR's summary: ICR news and Manchester news.
UK Higher Education's Pivotal Role in Cancer Genomics
This work exemplifies collaborative prowess between ICR London (part of University of London ecosystem) and University of Manchester's Cancer Research Centre. Funded by NIHR Manchester Biomedical Research Centre, it builds on UK's genomic infrastructure.
ICR's Professor Houlston heads cancer genomics; Manchester's Wedge leads data science. Their labs train PhD/postdocs in bioinformatics, with opportunities in research jobs. Such studies bolster UK's reputation, attracting talent via programs like UK university jobs.
Methodological Innovations Driving the Field Forward
The team refined signature extraction, using probabilistic models to deconvolute overlapping processes. They developed tools for SV signatures—a first comprehensive set—and transcriptional bias analysis, now on GitHub for academic reuse.
Challenges overcome: high computational load for 10k+ genomes; privacy via Genomics England secure environment. Future tools could integrate multi-omics for richer insights.
Clinical and Research Implications for Precision Oncology
Beyond immediate therapies, signatures trace tumor timing (clonal vs. subclonal), informing evolution models. For UK patients, routine WGS (via NHS Genomic Medicine Service) could personalize care, reducing trial-and-error.
Challenges: validation in diverse populations; cost of WGS (~£5k/genome). Solutions: AI acceleration, pan-UK biobanks.
Photo by Romina Ahmadpour on Unsplash
Future Horizons: From Map to Cure
Professor Houlston envisions: “The future... in understanding the story [mutations] tell.” Upcoming: integrate with proteomics; microbiome trials for colorectal; expanded HRD screening guidelines.
UK higher ed poised to lead, with calls for more genomics funding. Aspiring researchers: explore postdoc positions in cancer genomics.